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Summary
We used gene expression profiling to establish a molecular diagnosis of mantle cell lymphoma (MCL), to elucidate its
pathogenesis, and to predict the length of survival of these patients. An MCL gene expression signature defined a large
subset of MCLs that expressed cyclin D1 and a novel subset that lacked cyclin D1 expression. A precise measurement of
tumor cell proliferation, provided by the expression of proliferation signature genes, identified patient subsets that differed
by more than 5 years in median survival. Differences in cyclin D1 mRNA abundance synergized with INK4a/ARF locus
deletions to dictate tumor proliferation rate and survival. We propose a quantitative model of the aberrant cell cycle
regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy.

S I G N I F I C A N C E
From a mechanistic standpoint, our results demonstrate that mathematical models can reveal the synergism between oncogenic
events in a human cancer. The proliferation gene expression signature functioned as a quantitative integrator of multiple oncogenic
aberrations. As such, the proliferation signature was better at predicting length of survival than were other models based on the
individual oncogenic events. From a clinical standpoint, our gene expression-based model of survival provides the most precise
prognostic index yet described for MCL. Our survival model suggests that therapeutic modulation of the cell cycle has the potential
to significantly prolong the life of these patients.
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Introduction
Mantle cell lymphoma (MCL) was originally identified as a morphologically distinct subtype of non-Hodgkin’s lymphoma, and
subsequently the t(11;14) translocation was defined as a characteristic molecular feature of this lymphoma subtype (Campo et
al., 1999; Raffeld and Jaffe, 1991; Swerdlow and Williams, 2002;
Weisenburger and Armitage, 1996). This translocation leads to
overexpression of cyclin D1, a D-type cyclin that is not usually
expressed at high levels in normal B lymphocytes (Rosenberg
et al., 1991). Current WHO guidelines for the diagnosis of MCL
rely on morphological assessment supplemented with analysis
of cyclin D1 translocation or overexpression (Jaffe et al., 1999).
Cyclin D1 translocation and expression has been helpful in distinguishing MCL from other chronic B cell malignancies, such
as small lymphocytic lymphoma/chronic lymphocytic leukemia
(SLL/CLL), follicular lymphoma, and marginal zone lymphoma.
Nevertheless, some lymphomas that lack cyclin D1 expression
are morphologically similar to MCL and may be variant forms
of this lymphoma type (Yatabe et al., 2000).
MCL accounts for 6% of all non-Hodgkin’s lymphomas and
a higher fraction of deaths from lymphoma, given that it is an
incurable malignancy (Campo et al., 1999; Swerdlow and Williams, 2002; TNHLCP, 1997). The length of survival of MCL
patients following diagnosis is quite variable. The median survival in MCL is approximately 3 years, but some patients have
an aggressive disease to which they succumb in less than 1
year. Other patients have a comparatively indolent disease, and
some patients may survive more than 10 years.
Faced with this clinical heterogeneity, many attempts have
been made to develop prognostic markers of survival. Several
morphological subtypes of MCL have been recognized, and a
blastic variant of MCL has been associated with short survival
in several studies (Argatoff et al., 1997; Bosch et al., 1998;
Lardelli et al., 1990). High tumor cell proliferation has also been
associated with shorter survival (Argatoff et al., 1997; Bosch et
al., 1998; Raty et al., 2002; Velders et al., 1996), as has INK4a/
ARF locus deletion (Dreyling et al., 1997; Pinyol et al., 1998)
and p53 mutation or protein overexpression (Greiner et al., 1996;
Hernandez et al., 1996; Louie et al., 1995). However, the prognostic groups defined by each of these markers were still clinically heterogeneous, demonstrating that each marker alone
does not fully account for the clinical behavior of these tumors.
In the present study, our first goal was to establish a molecular diagnosis of MCL based on gene expression that could
reliably distinguish this disease from other lymphoma types.
With such a diagnostic test in hand, we investigated which
genes had expression patterns that correlated with length of
survival. We show that genes involved in proliferation have an
overriding influence on the clinical course and can be used
to construct a powerful predictor of survival. Additionally, we
demonstrate that the proliferation signature integrates several
oncogenic mechanisms in MCL that govern the cell cycle, leading us to propose a quantitative model for MCL pathogenesis.
Results
Molecular diagnosis of MCL
To establish a molecular diagnosis of MCL based on gene expression, we began by identifying lymphoma cases that were
morphologically consistent with this diagnosis upon pathologi-
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cal review. Since the t(11;14) translocation and cyclin D1 overexpression have been consistently associated with MCL, we measured cyclin D1 mRNA levels in each potential MCL case by
quantitative RT-PCR. Of the 101 cases with MCL histology, 92
expressed cyclin D1 mRNA, and these were considered the
“core” group of bona fide MCLs. We used Lymphochip DNA
microarrays (Alizadeh et al., 1999) to profile gene expression in
all 101 lymphoma cases with MCL morphology. For comparison,
we profiled gene expression in 20 cases of SLL and used previously published gene expression data from two subgroups of
diffuse large B cell lymphoma (DLBCL), germinal center B celllike (GCB) DLBCL (134 cases), and activated B cell-like (ABC)
DLBCL (83 cases) (Rosenwald et al., 2002). Several thousand
genes were differentially expressed between MCL and the other
lymphoma subtypes with high statistical significance (p ⬍
0.001), and those “MCL signature genes” that were most highly
and differentially expressed in MCL are shown in Figure 1A (a
complete listing of these genes is available at http://llmpp.nih.
gov/MCL).
To create a gene expression-based diagnostic test for MCL,
we developed a Bayesian statistical method that was able to
distinguish MCL from other lymphoma subtypes. In brief, we
began by identifying the most differentially expressed genes
between cyclin D1-positive MCL and each of the other lymphoma types. These differentially expressed genes were combined to form a series of binary predictors that estimated the
probability that a particular lymphoma sample was MCL or one
of the other lymphoma types. We used a cutoff of 90% probability in assigning a sample to a lymphoma type based on these
binary predictors.
To insure the reproducibility of our method, we divided the
cyclin D1-positive MCL cases into two equal groups: a “training
set” that was used to develop the MCL diagnostic test, and a
“validation set” that was used to evaluate the test. We optimized
the number of genes in each binary lymphoma type predictor
so as to minimize the number of classification errors when the
predictor was applied to the training set cases in a crossvalidation, leave-one-out fashion. We deliberately excluded cyclin D1
as a lymphoma type distinction gene because we wished to
apply our model to potential MCL cases that were cyclin D1negative. Using the optimized lymphoma type predictors, 100%
of the training set cases were correctly classified (Figure 1B).
When applied to the validation set, the model correctly classified
98% of the cyclin D1-positive MCL cases as MCL, thus establishing this method as a reliable MCL diagnostic test (Figure 1B).
We applied this MCL diagnostic test to 9 lymphoma cases
that were morphologically consistent with MCL but were negative for cyclin D1 expression by quantitative RT-PCR analysis.
Seven were classified as MCL, one was classified as GCB
DLBCL, and one was not assigned to any lymphoma group
based on the probability cutoff used. As shown in Figure 1C,
the 7 cyclin D1-negative MCL tumors were comparable to cyclin
D1-positive MCL tumors with respect to expression of 42 MCL
signature genes. Interestingly, 2 of these cyclin D1-negative
tumors expressed higher levels of cyclin D3, and 1 expressed
higher levels of cyclin D2 than were detected in cyclin D1positive MCLs. At present, the molecular mechanisms underlying the expression of other D-type cyclins in these cases are
unclear, but this finding suggests that these tumors may have
found alternative ways to increase cell cycle progression in the
absence of cyclin D1. Overall survival of patients with cyclin
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D1-positive MCL was not statistically different from that of patients with cyclin D1-negative MCL (Figure 1D).
A gene expression-based predictor of survival
We next used gene expression to develop a predictor of length
of survival following diagnosis of MCL. The median survival of
the patients with cyclin D1-positive MCL was 2.8 years, but the
lengths of survival were quite heterogeneous (Figure 1D). Many
patients died within the first 2 years following diagnosis, yet
15% (14/92) of the patients survived more than 5 years and 3
patients survived more than 10 years. It is important to emphasize that the diagnosis of MCL in these patients was based on
morphology, cyclin D1 expression, and expression of genes
that distinguish MCL from other non-Hodgkin’s lymphomas.
Thus, the differences in survival among these patients are unlikely to be due to the inadvertent inclusion of other lymphoma
types in our cohort.
We used a supervised approach to discover “survival prediction” genes with expression patterns that were associated with
length of survival among MCL patients in the training sets. The
expression levels of 48 genes correlated with survival with high
statistical significance (p ⬍ 0.001), and all of these were more
highly expressed in tumors from patients with short survival.
As in our previous analysis of survival of patients with DLBCL
(Rosenwald et al., 2002), we functionally classified the survival
prediction genes based on their membership in gene expression
“signatures.” A gene expression signature is a group of genes
that are coordinately expressed in association with a particular
biological process (Shaffer et al., 2001). Notably, 58% of the
survival prediction genes (28/48) belonged to the proliferation
gene expression signature. This signature is composed of genes
that are expressed at higher levels in dividing cells than in quiescent cells, including genes required for DNA replication, cell
cycle progression, and the metabolic demands of proliferation
(Shaffer et al., 2001). We further focused our attention on those
survival prediction genes that were most variably expressed
among the MCLs (i.e., in the top third of gene expression variance) in order to facilitate the subsequent analysis of these
genes by other methodologies; 34 genes satisfied this selection
criterion, of which 20 belonged to the proliferation signature.
We averaged the expression levels of these 20 genes to create
a proliferation signature average for each MCL case. Tumor cell
proliferation rate can also be estimated by the number of Ki67positive cells or by the mitotic index, and these data were available on 14 patients. As expected, the proliferation signature
average was correlated with the number of Ki67-positive cells
(r ⫽ 0.69) and the mitotic index (r ⫽ 0.62).
Within the training set, the proliferation signature average
was inversely correlated with survival with high statistical significance (1.92 ⫻ 10⫺5). Importantly, the proliferation signature
average also predicted survival of patients in the validation set
with high significance (7.44 ⫻ 10⫺5), thus demonstrating the
reproducibility of this gene expression-based predictor. When
all cases were considered together, this predictor correlated with
survival with a significance of p ⫽ 5.07 ⫻ 10⫺9. None of the other
survival prediction genes from the original set of 48 improved
the prognostic ability of the proliferation signature average in
multivariate models. Of note, we could also construct a model
from only 4 proliferation signature genes (CDC2, ASPM, tubulin
␣, CENP-F) that predicted length of survival with high statistical
significance on the total set of cases (p ⫽ 2.67 ⫻ 10⫺8).
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To visualize the predictive power of our survival model, we
ranked the patients according to the expression of the proliferation signature genes in their tumors, and divided them into 4
equal quartiles. Figure 2B shows Kaplan-Meier plots of overall
survival of patients in each of these quartiles, within the training
set, the validation set, and the total set of cases. These plots
indicate that the proliferation signature can identify patient subsets with strikingly different survival times. The median survival
times of patients in the four quartiles were: 6.71 years (quartile
1), 3.28 years (quartile 2), 2.31 years (quartile 3), and 0.83 years
(quartile 4). It is important to emphasize that the quartile method
that we used to group MCL patients is merely a way of illustrating
the quantitative relationship between proliferation and survival.
The proliferation signature average is a continuous variable that
assigns, for each patient, a discrete probability of survival at
every time point following diagnosis. The proliferation signature
average varied over a 13.5-fold range and a 2-fold increase in
the proliferation signature average corresponded to a 3.6-fold
increased relative risk of dying.
Several histological subtypes of MCL can be discerned, and
these have been shown to differ with respect to proliferation
rate and survival (Argatoff et al., 1997; Bosch et al., 1998).
We subdivided our MCL cases by morphology into classical
(68.4%), blastic (9.8%), pleomorphic (6.5%), and small cell
(9.8%) subtypes. As expected, the cases with blastic morphology had the highest expression of the proliferation signature
(Figure 3A) and the shortest survival (Figure 3B). However, the
morphological categorization of MCL was a much weaker predictor of survival (p ⫽ 5.7 ⫻ 10⫺3) than was the proliferation
signature.
The proliferation signature integrates oncogenic
events associated with survival
Having related the proliferation signature to overall survival in
MCL, we searched for molecular mechanisms that might explain
the variable proliferation of MCLs. We noted that the mRNA
expression of the cyclin D1 coding region, as measured by a
quantitative RT-PCR assay, was higher in more proliferative
MCLs (p ⫽ 1.4 ⫻ 10⫺4; Figure 4A). Further, the abundance of
cyclin D1 coding region mRNA was a univariate predictor of
survival (p ⫽ 4.69 ⫻ 10⫺4), but was not as strong a prognostic
marker as the proliferation signature (Figure 4E). The expression
of cyclin D1 coding region mRNA was correlated with proliferation (p ⫽ 1.4 ⫻ 10⫺4), and therefore did not add to the prognostic
strength of the proliferation signature in a 2-component model.
These results suggests a direct relationship between cyclin D1
expression levels and proliferation rate in MCL, and demonstrate
that the length of survival of MCL patients depends upon quantitative differences in progression from G1 to S phase of the cell
cycle.
MCLs can express various cyclin D1 mRNA isoforms that
all include the cyclin D1 coding region but that differ in the
length of their 3⬘ untranslated regions (UTRs) (Figure 4G). The
4.5 kb mRNA isoform has an extended UTR that includes an
AT-rich segment with the potential to decrease mRNA stability
(Lebwohl et al., 1994; Lin et al., 2000; Rimokh et al., 1994). Some
MCLs have alterations in the cyclin D1 genomic sequences that
encode the 3⬘ UTR region, and these cases do not express the
4.5 kb mRNA isoform, but instead express a 1.7 kb mRNA
isoform or other short mRNAs that lack the potential mRNA
destabilizing element in the 3⬘ UTR (Bosch et al., 1994; de Boer
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Figure 2. A gene expression-based predictor of
survival
A: Relative expression of 20 proliferation signature genes that were used to compute the proliferation signature average. Cyclin D1-positive
MCL cases are ordered according to their expression of the proliferation signature average.
The color scale depicts gene expression over a
4-fold range.
B: Kaplan-Meier plots of overall survival according to a survival predictor based on the proliferation signature average. Separate plots are
shown for patients in the training set and the
validation set and for all patients combined. For
visualization, patients were ranked according to
their proliferation signature average and divided
into 4 equal quartiles.

et al., 1995; Rimokh et al., 1994; Seto et al., 1992; Withers et
al., 1991). On the Lymphochip DNA microarray, the cyclin D1
features correspond to the extended 3⬘ UTR, and therefore can
only detect expression of the 4.5 kb mRNA. In contrast, the
quantitative RT-PCR assay for the cyclin D1 coding region can
detect shorter isoforms lacking the extended 3⬘ UTR as well as
the 4.5 kb isoform.

With some MCL samples, we obtained little if any signal
from the cyclin D1 3⬘ UTR features on the microarray, yet these
same samples had abundant expression of the cyclin D1 coding
region as assessed by the quantitative RT-PCR assay (Figure
4A). This pattern suggests that these MCL tumors preferentially
express the short cyclin D1 mRNA isoforms lacking the extended 3⬘ UTR. Notably, the MCLs with this expression pattern

Figure 1. Molecular diagnosis of mantle cell lymphoma
A: Hierarchical clustering of expression measurements from 42 MCL signature genes that are more highly expressed in 92 MCL samples than in 20 SLL, 83
ABC LBCL, and 134 GCB DLBCL samples (see text for details). Each column represents a single lymphoma specimen, and each row represents expression
of a single gene. Red squares indicate increased expression and green squares indicate decreased expression relative to the median expression level
according to the color scale shown. The right panel shows the median gene expression for the 42 MCL signature genes in each of the lymphoma subgroups.
B: Performance of the gene expression-based diagnostic test for MCL in each of the three models (MCL versus ABC DLBCL, MCL versus GCB DLBCL, and
MCL versus SLL) in the “training set” and in the “validation set” of cases.
C: Expression of MCL signature genes in seven cyclin D1-positive and seven cyclin D1-negative lymphoma cases. Cyclin D1-negative cases had MCL
morphology and immunophenotype and were classified as MCL based on their gene expression profile. Shown below is the relative gene expression of
cyclin D1 (as measured by quantitative RT-PCR) and cyclins D2 and D3 (as measured by DNA microarray analysis).
D: Kaplan-Meier estimates of overall survival of patients with cyclin D1-positive and cyclin D1-negative MCL.
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Figure 3. Proliferation and survival rates in different histological subtypes of MCL
A: Proliferation signature averages in the classic, blastic, pleomorphic, and small cell subtypes of MCL. The dots represent the mean value within each
class, and the bars represent the standard error of that mean estimate.
B: Kaplan-Meier plots of overall survival of patients in different histological MCL subtypes.

were generally among those with high proliferation (Figure 4A).
Based on levels of cyclin D1 3⬘ UTR expression, we defined a
“3⬘ UTR low” group of 17 MCL cases and a “3⬘ UTR high” group
of 75 MCL cases (Figure 4B). The 3⬘ UTR low group had a 1.58fold higher level of cyclin D1 coding region mRNA than did the
3⬘ UTR high group (p ⫽ 5.4 ⫻ 10⫺5), thus providing one potential
molecular mechanism for the variable expression of cyclin D1
coding region mRNAs (Figure 4C). Further, the 3⬘ UTR low group
had a 1.83-fold higher expression of the proliferation signature
(p ⫽ 1.3 ⫻ 10⫺7; Figure 4D) and a shorter survival than the 3⬘
UTR high group (p ⫽ 7.97 ⫻ 10⫺5; Figure 4F).
We next investigated whether deletions of tumor suppressor
genes were associated with proliferation rate and survival in
MCL. We used a quantitative PCR assay to detect genomic
loss of one or both alleles of the INK4a/ARF locus, which encodes two tumor suppressors, p16INK4a and p14ARF. INK4a/ARF
locus deletions were detected in 21% (18/85) of the cases and
were preferentially observed among the more proliferative MCLs
(Figure 5A). The INK4a/ARF locus can also be transcriptionally
silenced by the polycomb family protein BMI-1 (Jacobs et al.,
1999), and BMI-1 is amplified and/or overexpressed in some
MCLs (Bea et al., 2001). Notably, BMI-1 was overexpressed in
some highly proliferative MCLs that lacked INK4a/ARF locus
deletion (Figure 5A).
We next tested whether the proliferation rate of MCL tumors
could be modeled using a combination of the INK4a/ARF locus
deletional status and the expression of cyclin D1 coding region
mRNA. Both of these parameters added independently to a
model of survival: cyclin D1 coding region expression added to
the significance of a model based on INK4a/ARF locus deletion
alone (p ⫽ 2.6 ⫻ 10⫺3), and INK4a/ARF locus deletion added
to the significance of a model based on cyclin D1 coding region
expression alone (p ⫽ 3.6 ⫻ 10⫺5). This finding suggests that
increased cyclin D1 expression and INK4a/ARF locus deletion
cooperate mechanistically to increase the proliferation rate (see
Discussion). INK4a/ARF locus deletions were also associated
with shorter survival (p ⫽ 4.88 ⫻ 10⫺4; Figure 5B). Again, INK4a/
ARF locus deletional status and cyclin D1 coding region expression added independent predictive power to a combined statis-
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tical model of survival, such that the combined model had a
greater significance (p ⫽ 3.59 ⫻ 10⫺6) than models of survival
based on either of these components alone (Figure 5C).
Deletional events at the p53 and ATM loci had distinct but
overlapping distributions with respect to each other and with
respect to INK4a/ARF locus deletions (Figure 5A). p53 deletions
were found in 9 MCL cases (11%), and concurrent deletions
of INK4a/ARF locus and ATM were found in 3 and 6 cases,
respectively. ATM deletions were more frequent among the
MCLs, occurring in 30 cases (35%), and were concurrent with
INK4a/ARF locus and p53 deletions in 8 and 6 cases, respectively. These findings suggest that loss of these tumor suppressor genes provided nonredundant selective advantages to the
MCLs during the natural histories of these lymphomas. p53
deletions were not strongly associated with proliferation (Figure
5A) or survival (p ⫽ 0.25; data not shown), although the number
of p53 deletional events in our series was small, and some
MCL cases may have mutations of p53 without deletion. ATM
deletions were present in tumors with both low and high proliferation rates (Figure 5A), and had no apparent relationship to
survival (p ⫽ 0.66; data not shown).
Discussion
We have taken a quantitative approach to understand the pathogenesis of MCL and to account for the variable survival of these
patients. By precisely measuring the expression of genes associated with proliferation, we found that the degree of tumor cell
proliferation provides a powerful predictor of survival for this
lymphoma. Further, our approach provides a quantitative rather
than qualitative framework for the molecular pathogenesis of
this disease, in which higher cyclin D1 mRNA levels are reflected
in higher tumor cell proliferation and shorter survival.
The defining oncogenic event in most MCLs is translocation
and overexpression of cyclin D1, and this shared pathogenetic
feature was central to the success of our quantitative approach.
Using an RT-PCR assay, we defined a cohort of patients whose
tumors expressed cyclin D1 and found that they also expressed
a set of MCL signature genes that distinguished this lymphoma
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Figure 4. Relationship between cyclin D1 expression, proliferation, and survival in MCL
A: Relative cyclin D1 mRNA expression of the coding region (measured by quantitative RT-PCR, upper panel) and of the 3⬘ UTR (measured by DNA
microarray analysis). The 92 cyclin D1-positive MCL cases are ordered according to their proliferation signature average (lower panel). The cyclin D1
expression is depicted over a 9-fold range, whereas the proliferation signature expression is depicted over a 4-fold range.
B: Histogram of cyclin D1 3⬘ UTR levels. Shown is a cutpoint that divides the MCL cases into a “3⬘ UTR low” group (17 cases) and a “3⬘ UTR high” group (75
cases).
C: Level of cyclin D1 coding region mRNA in the “3⬘ UTR low” and “3⬘ UTR high” groups of MCL. The dots represent the mean value within each class, and
the bars represent the standard error of that mean estimate.
D: Proliferation signature averages of MCL cases in the “3⬘ UTR low” and “3⬘ UTR high” groups of MCL. The dots represent the mean value within each
class, and the bars represent the standard error of that mean estimate.
E: Kaplan-Meier estimates of overall survival according to the level of cyclin D1 coding region mRNA expression.
F: Kaplan-Meier plot of overall survival according to cyclin D1 3⬘UTR expression.
G: The cyclin D1 locus: alternative 3⬘ polyadenylation sites can result in the expression of a short (1.7 kb) and a long (4.5 kb) cyclin D1 mRNA.

CANCER CELL : FEBRUARY 2003

191

R E P O R T

Figure 5. Deletions of INK4a/ARF, ATM, and p53
loci in MCL
A: Genomic loss of one or both alleles of the
INK4a/ARF, ATM, and p53 loci as measured by
quantitative PCR. MCL cases are ordered by
their proliferation signature averages, and deletions are indicated by yellow squares. Black
squares indicate wild-type configuration of the
genomic loci, and gray squares indicate missing
data. BMI-1 expression is depicted over a 9-fold
range.
B: Influence of INK4a/ARF locus deletion on overall survival.

type from others. By basing our molecular diagnosis on the
expression of cyclin D1 and the MCL signature genes, we could
be confident that we were studying patients with highly related
cancers, which is critical when searching for the molecular determinants of survival.
The MCL gene expression signature further allowed us to
identify a new subtype of MCL that is cyclin D1-negative. The
existence of cyclin D1-negative MCL has been controversial,
since other methods of detecting cyclin D1 translocations or
expression vary in sensitivity, and since other lymphoid malignancies can express cyclin D1. We identified a group of lymphomas that were not only morphologically indistinguishable from
cyclin D1-positive MCLs, but also shared expression of MCL
signature genes. These patients with cyclin D1-negative MCL
did not differ significantly in survival from patients with cyclin
D1-positive MCL. Interestingly, some of the cyclin D1-negative
MCLs expressed either cyclin D2 or D3, suggesting that these
cyclins can functionally substitute for cyclin D1 in MCL. At present, we do not know whether the expression of the other D-type
cyclins in these cases is due to genomic rearrangements of
these genes or to increased transcription. Given the importance
of the G1/S phase transition in MCL, it is highly likely that all
of the cyclin D1-negative MCL tumors have acquired some
mechanism to accelerate entry into S phase.
Among patients with cyclin D1-positive MCL, the proliferation signature was the sole gene expression feature that was
significantly associated with survival. Using the proliferation signature average as a metric, we identified one quartile of MCL
patients who had a median survival of 6.7 years, which is exceptionally long for this incurable malignancy. At the other end
of the spectrum, we identified a quartile of patients who had
particularly aggressive tumors and a median survival of only 0.8
years. This 5.9-year difference in survival highlights the potential
value of the proliferation gene expression signature as a prognostic test in MCL. By contrast, previous analyses of tumor cell
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proliferation in MCL relied on semiquantitative methods such
as the mitotic index or immunohistochemical staining for Ki67
to define patient groups that differed in survival by only 2.1–2.7
years (Argatoff et al., 1997; Bosch et al., 1998; Raty et al., 2002;
Velders et al., 1996).
Since our quantitative method accounts more fully for the
varying survival of MCL patients, it could prove useful in the
clinical management of these patients. Since the proliferation
signature can be faithfully represented by as few as 4 genes,
a limited set of quantitative RT-PCR assays could be used to
assess tumor proliferation rate. In particular, we suggest that
clinical trials in MCL should incorporate a quantitative measure
of tumor proliferation rate. This would enable a direct comparison of the patients enrolled in different clinical trials and would
provide a rational basis by which to compare trial results.
Various intensified treatments are being evaluated in MCL,
including autologous and allogeneic bone marrow transplantation, modified chemotherapeutic regimens, and radioimmunotherapy (Barista et al., 2001; Gopal et al., 2002; Leonard et al.,
2001). Our results suggest that it may be beneficial to stratify
patients for entry into clinical trials of these regimens according
to the expression of proliferation signature genes in their tumors.
Clinical trials of intensified regimens might be designed to enroll
only those patients whose tumor proliferation rate predicts an
exceedingly short survival. Intensified regimens may not be appropriate for patients whose tumor proliferation rate predicts a
longer survival, since these regimens may not prolong the survival of these patients and may unnecessarily expose them
to treatment-related toxicities. Rather, these patients could be
managed conservatively, with relatively nontoxic therapies given
only as clinically indicated.
In addition to its value in prognosis, the proliferation signature proved very useful in establishing a quantitative model
of MCL pathogenesis. In particular, the proliferation signature
quantitatively integrated the effects of cyclin D1 expression and
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deletion of the INK4a/ARF locus. However, our statistical model
based on cyclin D1 expression and INK4a/ARF deletions accounted for only 32% of the variation in the proliferation signature average (data not shown), and therefore the proliferation
signature may also reflect additional oncogenic events that are
as yet unknown.
Higher expression of cyclin D1 mRNA was correlated with
increased proliferation and decreased survival time. The importance of this oncogenic mechanism in MCL has been overlooked
since previous studies have used only semiquantitative methods
to assess cyclin D1 expression and tumor proliferation. We
noted that many of the highly proliferative MCL tumors expressed mRNA species that contained the cyclin D1 coding
region but not the extended 3⬘ UTR region, and this was associated with higher levels of cyclin D1 coding region expression.
MCLs and other cancers have been shown to variably express
cyclin D1 mRNA isoforms that differ in the length of their 3⬘
UTRs. The extended 3⬘ UTR of the 4.5 kb cyclin D1 isoform
contains AT-rich sequences that can modulate the stability of
the mRNA, and short cyclin D1 mRNA isoforms lacking this
region are more stable (Lebwohl et al., 1994; Lin et al., 2000;
Rimokh et al., 1994). In some MCLs, the genomic region corresponding to the extended 3⬘ UTR is deleted or rearranged, and
these cases lack expression of the 4.5 kb mRNA isoform (de
Boer et al., 1995; Rimokh et al., 1994; Seto et al., 1992; Withers
et al., 1991). However, in some cells, the 4.5 and 1.7 kb isoforms
coexist, and their relative abundance may be regulated by alternative polyadenylation and cleavage (Xiong et al., 1991). Regardless of the mechanism, our data demonstrate that selective
expression of short cyclin D1 mRNA isoforms is a pathogenetic
mechanism that is associated with increased cyclin D1 expression, more rapid proliferation, and shorter survival.
The relationship between increased cyclin D1 expression
and increased proliferation suggests a quantitative model for
the G1/S phase transition. In this model, an increase in the
intracellular concentration of cyclin D1 promotes its assembly
into active kinase complexes with cdk4 and cdk6 (cyclin D1/
cdk4[6]), which would enhance the frequency at which the cell
enters S phase by two mechanisms (reviewed in Sherr and
McCormick, 2002). Cyclin D1/cdk4(6) kinases phosphorylate
the retinoblastoma (Rb) gene product and thereby promote the
release of E2F transcription factors that are required in S phase.
Further, cyclin D1/cdk4(6) complexes interact with the cyclindependent kinase inhibitors p21 and p27kip1 and titrate these
factors away from cyclin E/cdk2 kinase complexes. Whereas
p21 and p27kip1 are potent inhibitors of cyclinE/cdk2, they
fail to inhibit cyclin D1/cdk4(6). Increased cyclin E/cdk2 kinase
activity promotes S phase entry by phosphorylating Rb and
can sustain cell cycle progression by phosphorylating p27kip1,
leading to its degradation in the proteosome. In keeping with
this model, most p27kip1 in MCL cells is biochemically associated with cyclin D1 (Quintanilla-Martinez et al., 2003).
Our findings highlight the quantitative sensitivity of the G1/S
phase transition to changes in D-type cyclin concentration. This
cell cycle transition appears to behave like a rheostat regulated
by cyclin D1 kinase complex levels rather than an on/off switch
that is activated when a threshold level of cyclin D1 is achieved
(see Sherr and Roberts, 1995, 1999 for a complete discussion).
In this model, the fraction of cells in the tumor clone that are
in G1 phase, and consequently the tumor proliferation rate,
would be influenced quantitatively by the abundance of cyclin
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D1 kinase complexes. Our data demonstrate that small changes
in the expression of D-type cyclins can have significant effects
on tumor cell proliferation and the clinical course of cancer
patients.
High expression of the proliferation signature in MCL was
also associated with deletion of the INK4a/ARF locus. This locus
encodes two structurally unrelated tumor suppressors, p16INK4a
and p14ARF (Sherr and McCormick, 2002), and deletions of this
genomic region in MCL typically inactivate both the p16INK4a and
p14ARF genes and are frequently homozygous (Dreyling et al.,
1997; Pinyol et al., 1997, 1998, 2000). Further, the p16INK4a gene
does not sustain point mutations in MCLs as it does in melanoma
and other cancers (Pinyol et al., 1997, 2000). Finally, we and
others (Bea et al., 2001) observed overexpression of the BMI-1
gene in MCLs that lacked deletion of the INK4a/ARF locus,
which is notable since BMI-1 represses transcription of both
p16INK4a and p14ARF (Sherr and McCormick, 2002). These considerations suggest that the INK4a/ARF deletions in MCL may be
selected to circumvent the actions of both p16INK4a and p14ARF.
p16INK4a regulates the G1/S phase transition by forming binary complexes with cdk4 and cdk6, thereby preventing these
subunits from associating with molecular chaperones that promote their association with D-type cyclins (reviewed in Sherr
and McCormick, 2002). p16INK4a deletion and increased cyclin
D1 expression may therefore promote the G1/S phase transition
by the same mechanism. Nonetheless, our statistical models
demonstrated that cyclin D1 expression and INK4a/ARF deletions cooperated to quantitatively increase proliferation and
shorten survival. One model to account for this oncogenic synergism would propose that the presence of wild-type levels of
p16INK4a blunts the effect of increased cyclin D1 expression by
preventing cyclin D1 from forming active kinase complexes.
Although many cancer types have disruption in only one component of the Rb pathway (Sherr and McCormick, 2002), our results
suggest that some cancers may accumulate multiple oncogenic
lesions that cooperate to quantitatively interfere with this pathway and promote proliferation.
Studies of mouse strains with selective disruption of the
p14ARF gene demonstrate that p14ARF also regulates proliferation.
p14ARF-deficient mouse embryo fibroblasts and pre-B cells divide more rapidly than their wild-type counterparts and fail to
senesce during repeated passaging in vitro (Kamijo et al., 1998;
Randle et al., 2001). Further, in transgenic mice overexpressing
c-myc, p14ARF-deficiency accelerates lymphoma formation and
the proliferation rate of the malignant B cells ex vivo (Eischen
et al., 1999; Schmitt et al., 2002). Although the mechanisms
underlying the enhanced proliferation of p14ARF-deficient cells
are not completely understood, these observations suggest that
loss of p14ARF may contribute to the enhanced proliferation of
INK4a/ARF-deleted MCL tumors.
An important function of p14ARF is to augment p53 function
by antagonizing MDM2 (Sherr and McCormick, 2002), and loss
of this p14ARF function may contribute to the enhanced proliferation and shorter survival of MCL patients with INK4a/ARF deletions. p14ARF is induced by a variety of oncogenes that promote
inappropriate proliferation, leading to a p53-dependent cell cycle arrest or apoptosis (Kamijo et al., 1997, 1998). In MCL tumors
with wild-type INK4a/ARF loci, it is conceivable that some oncogenic stimuli may activate p14ARF and constrain proliferation. In
this scenario, MCL tumor cells that sustain p14ARF deletions
would have a selective advantage. Our observation that INK4a/

193

R E P O R T

ARF locus deletions and cyclin D1 expression synergize to predict the proliferation signature may therefore reflect a cooperation between the p53 pathway and the RB pathway in controlling
cell cycle progression. However, we found that some MCL tumors had deletions of both the INK4a/ARF and p53 loci, suggesting that p53 deletion may provide additional selective advantages, such as evasion of apoptosis.
Though many of the oncogenic events in MCL are designed
to promote S phase entry, deletions of the ATM tumor suppressor gene appear to play a different role. Roughly one-third of
the MCL tumors in our study had ATM deletions, irrespective
of tumor proliferation rate, INK4a/ARF locus deletional status,
and cyclin D1 expression and survival. This finding suggests
that the tumor suppressor role of ATM in MCL is unrelated
mechanistically to G1/S phase checkpoint. ATM is required for
activation of p53 in response to DNA damage and abnormal
telomeres, and during normal immunoglobulin V-D-J recombination (Karlseder et al., 1999; Kastan et al., 1992; Perkins et
al., 2002). However, ATM deletions coincided with p53 deletions
in several MCL cases, suggesting that loss of these genes may
serve distinct functions in the pathogenesis of some MCLs.
Finally, our data provide quantitative insights into the potential of cell cycle inhibitors in the therapy of MCL. Although cell
cycle inhibitors would not necessarily be curative in MCL, it is
possible that they could alter its natural history, yielding a
chronic lymphoproliferative disease that could be managed
conservatively. Could, for example, a cell cycle inhibitor shift a
patient’s lymphoma from the last to the first quartile of the
proliferation signature average, thereby prolonging the patient’s
survival by more than 5 years? An inhibitor targeting the basic
cell cycle machinery would likely require careful dose titration
in order to limit toxicity during chronic administration. Alternatively, it is possible that inhibitors that target the G1/S checkpoint by disrupting cyclin D1/cdk4(6) complexes could be administered chronically, and might turn MCL into a clinically
manageable disease.
Experimental procedures
Patients
Tumor biopsies from 101 untreated patients with no history of a previous
lymphoma were included in the present study, according to a protocol
approved by the National Cancer Institute institutional review board. Tumor
histology was reviewed by a panel of 8 hematopathologists, and 92 biopsy
specimens were classified as mantle cell lymphoma, based on established
morphologic and immunophenotypic criteria (Jaffe et al., 2001). All of these
92 cases showed overexpression of cyclin D1 mRNA by a quantitative RTPCR assay and, in most cases, immunohistochemistry demonstrated overexpression of cyclin D1 also on the protein level. In the remaining nine
lymphoma specimens, the morphology and immunophenotype of the tumor
cells were consistent with the diagnosis of MCL, but there was no evidence
of the t(11;14) translocation or cyclin D1 protein expression. All nine of these
cases were negative for cyclin D1 mRNA expression by quantitative RTPCR. Only data obtained from the 92 patients with cyclin D1-positive MCL
were used to create the gene expression-based predictor of survival. Among
these 92 patients, 72 were male and 19 female (no information was available
on one patient), the median age at diagnosis was 61.5 years (range 38 to 92.5
years) and median survival was 2.8 years. 84 patients received multiagent
chemotherapy as needed symptomatically, 6 received no treatment, and no
information on treatment was available in 2 patients.
Microarray procedures
Lymphochip DNA microarrays (Alizadeh et al., 1999) containing 12,196 cDNA
elements were used to quantitate mRNA expression in the lymphoma sam-
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ples, as described previously (Rosenwald et al., 2002). The complete gene
expression data set is available at http://llmpp.nih.gov/MCL.
Real-time quantitative PCR
To measure cyclin D1 mRNA expression by real-time quantitative RT-PCR,
an aliquot of the mRNA used for the microarray experiments was diluted to
approximately 0.5 ng/l. 5 l of the diluted mRNA were used for each
RT-PCR reaction using TaqManTM reagents and analyzed on an Applied
Biosystems Thermal Cycler. All samples were run in triplicate, and a probe
for the ␤2-microglobulin gene was chosen as a reference. Primers and
Taqman probes for both ␤2-microglobulin and the coding region of cyclin
D1 have been described previously (Bijwaard et al., 2001).
To detect genomic loss of the INK4a/ARF, ATM, and p53 tumor suppressor loci in the tumor specimens, we performed quantitative real-time PCR
assays using genomic DNA. The REL locus on chromosome 2p was chosen
as a reference gene based on comparative genomic hybridization studies
that showed only infrequent genomic alterations in this chromosomal region
in MCL (Bea et al., 1999; Bentz et al., 2000). Eight control DNA samples
were prepared from peripheral blood mononuclear cells of 5 different healthy
volunteers. The ratios of INK4a/ARF locus, ATM, and p53 amplification relative to REL amplification were calculated for each control sample. We used
these control ratios to establish cutoff ratios that we used to assess tumor
DNAs for genomic deletions. For each gene, this cutoff ratio was set as the
mean ratio minus 3 standard deviation units; the cutoffs for the INK4a/
ARF locus/REL, ATM/REL, and p53/REL ratios were 0.67, 0.72, and 0.7,
respectively. A tumor DNA sample that yielded an amplification ratio below
the cutoff ratio for a particular tumor suppressor gene was considered to
have a genomic deletion of that gene.
We used previously described primer and TaqMan probe sets for the
INK4a/ARF locus that were situated in exonic regions that are shared by
p16INK4a and p14ARF (Labuhn et al., 2001). The primers used for the REL locus
have also been described (Goff et al., 2000). Primers for ATM amplification
were 5⬘-CCCAGACCGCCAATCTCAT (sense) and 5⬘-ATGGAGTGAGGAGA
GGGAGGA (antisense), and for p53, 5⬘-GGGACCTCTTATCAAGTGGAAA
(sense) and 5⬘-CCCAATTGCAGGTAAAACAGTCA (antisense). Gene-specific
fluorescent probes for ATM and p53 were 5⬘-FAM-CACCCCTCCAGAGTGG
CCCTTGA-TAMRA (sense) and 5⬘-FAM-TTTCCAGTCTAACACTCAAAATGC
CGTTTTCTT-TAMRA (sense), respectively.
Statistical methods
Bayesian formulation of a discrimator between two
lymphoma subtypes
The method we used to formulate our predictor of MCL was based on a
variation of the compound covariate predictor (Radmacher et al., 2002).
Although our complete method involved the distinction between MCL and
several different classes of samples, we begin by describing a general
method for estimating the probability that a given sample is in one of two
groups, based on data from a fixed training set.
We begin with a gene selection step. For each gene in our training set,
we calculated the t statistic for the difference in the expression of that gene
between the two groups. After our data set was so reduced to include
only unique genes, we choose the k genes with most statically significant t
statistics to use in our predictor. In order to avoid redundancy, when multiple
spots for a given gene were found on the array, we only considered the
spot that gave the most statistically significant t statistic. This resulted in a
list of k unique genes that were variably expressed between the two groups.
The method we used to choose k will be discussed later.
Given a training sample, the standard 2-group compound covariate
predictor associates with each sample a compound covariate score (CCS)
given by
CCS(X) ⫽

k

兺 t jX j ,

j⫽ 1

where tj is the t statistic for the two-group comparison of the log ratios for
gene j in the training set, and Xj is the log ratio for gene j of the sample.
This sum is taken over the k most significant t statistics. This produces a
score for which high values indicate likely membership in group 1 and low
values indicate likely membership in group 2.
Radmacher et al. suggest classifying a new sample based on whether the
CCS of this new sample was closer to the median of the CCSs in each group.
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This works well, but does not allow one to make a statement concerning the
amount of confidence one has in such an assignment. According to Bayes’
rule (Bayes, 1763), we can estimate the probability of a new sample Y being
within one of the groups as
P(Y in Group 1|CCS(Y) ⫽
P(CCS(Y)|Y in Group 1)
.
P(CCS(Y)|Y in Group 1) ⫹ P(CCS(Y)|Y in Group 2)
Strictly speaking, there should be additional terms indicating the general
prevalence of group 1 and group 2 in the population at large, but since we
make no claims as to the representative nature of our patient sample, we
eliminated these terms, inherently assuming that Group 1 and Group 2 were
equally prevalent.
Since CCS(X) is the linear combination of multiple measurements, it is not
unreasonable to assume that the distribution of CCS(X) within each subgroup
will be approximately normal. So if we let M1 and M2 be the sample means
of CCS(X) within group 1 and group 2 of the training set, and s12 and s22
the respected sample variances, we can make the following estimate:
P(Y in Group 1) ⫽
φ(CCS(Y); M1,s12)
φ(CCS(Y); M1,s12) ⫹ φ(CCS(Y); M2,s22)
where φ represents the normal density.
φ(x; , 2) ⫽

1

e⫺(x⫺)/2 .
2

√2

For ease in notation we write
P1(Y) ⬅ P(Y in Group 1).
Formulation of a gene expression-based MCL diagnostic test
We began by equally dividing the gene expression data from MCL and other
lymphoma samples into a training set and a validation set. The training set
consisted of 46 MCL samples, 42 ABC samples, 67 GCB samples, and 11
SLL samples. The validation set was similarly composed, but had one fewer
ABC sample. Since our goal was to determine which genes other than cyclin
D1 were related to MCL, we excluded all cyclin D1 clones from this analysis.
In generating an MCL versus non-MCL predictor, a simple two class
predictor would be insufficient, since there was a great deal of structure
within the non-MCL subset. Instead, we generated 3 separate 2-group predictors: MCL versus ABC, MCL versus GCB, and MCL versus SLL.
Each model was trained only on those elements of the training set that
matched the model (i.e., only the MCL and GCB cases were used to train
the MCL versus GCB model.) Since a priori the optimal value of k, the number
of genes included in a given predictor, was unknown, we used leave-oneout crossvalidation (Hills, 1966) to optimize this value. According to leaveone-out crossvalidation, one sample at a time is removed from the training
set, and the remaining samples are used to form a predictor, which is applied
to the removed sample. This is repeated each time, reselecting genes and
reformulating the predictor, until each sample has been left out once. This
method was repeated for different values of k, and we choose the value
that gave us the lowest total leave-one-out error probability for a given
model. For example for the GCB versus MCL model, we chose the value of
k that minimized

兺

PMCL (Y) ⫹

Y in GCB

兺

PGCB (Y)

Y in MCL

Where the probabilities are computed based on a training set of all samples
except Y. This optimization resulted in k ⫽ 9 for the GCB versus MCL
predictor, k ⫽ 20 genes for ABC versus MCL predictor, and k ⫽ 85 for the
SLL versus MCL predictor.
Using these k values, we now used the entire training set to generate the
three predictors and applied it to the training set. We defined a patient, Y,
as MCL only if PMCL(Y ) ⬎ 0.9 for all three predictors. This resulted in only
one misclassification, in which an MCL predictor had PABC(Y ) ⬎ 0.9. Incidentally, we also observed that all of the non-MCL patients were correctly
assigned by their respective predictors with p ⬎ 0.9. (i.e., PGCB[Y] ⬎ 0.9 for
all Y in GCB on the validation set, etc.).
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Other statistical methods
Survival curves and median survival times were estimated using the KaplanMeier method. When estimating the association of parameters with survival,
Cox proportional hazards models were fit. For continuous variables, (proliferation and cyclin D1 coding region expression), the likelihood ratio p value
was reported. For the categorical variables (tumor histology, high/low cyclin
D1 3⬘ UTR, INK4a/ARF deletion, p53 deletion, and ATM deletion), the p
value from the log rank test was used. A Cox model was also fit to the
combination of the cyclin D1 coding region expression and an indicator of
INK4a/ARF deletion. For the purpose of displaying survival curves in Figure
5C, the samples were ranked according to this model and divided into
quartiles. A likelihood ratio p value was reported from the combined model.
A Spearman rank correlation test was used to indicate the association
between proliferation and expression of the cyclin D1 coding region. When
determining differences between the high/low cyclin D1 3⬘ UTR in proliferation and cyclin D1 coding region expression, the p value from a 2-sided t
test was reported. t tests were also used to determine the extent to which
genes were differentially expressed between MCL and each other lymphoma
subtypes. An ANOVA model was used to determine the extent to which
INK4a/ARF locus deletion and cyclin D1 coding region expression added
constructively in their association with proliferation.
In forming the predictor of survival, we used those genes that were
found in the proliferation signature, were associated with poor prognosis in
the training set (p ⬍ 0.001 according to a Wald test), and had larger variance
across the samples of the training set than 2/3 of the genes. When multiple
Lymphochip microarray features representing the same gene were found to
satisfy these conditions, only the feature that was most significantly associated with survival on the training set was used. No survival information from
the validation set was used to generate the gene list. The expression data
for each of these genes were mean centered across all samples, and the
proliferation signature average for a given sample was computed as the
average of these mean centered observations. Missing values for genes
were excluded in taking this average.
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